US Bancorp DE Buys 607 Shares of Enovis Co. (NYSE:ENOV)

US Bancorp DE grew its stake in Enovis Co. (NYSE:ENOV) by 3.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,569 shares of the company’s stock after acquiring an additional 607 shares during the period. US Bancorp DE’s holdings in Enovis were worth $815,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of ENOV. UMB Bank n.a. grew its stake in Enovis by 128.2% in the fourth quarter. UMB Bank n.a. now owns 778 shares of the company’s stock worth $34,000 after purchasing an additional 437 shares in the last quarter. Pinnacle Bancorp Inc. lifted its holdings in shares of Enovis by 54.5% in the 4th quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company’s stock worth $37,000 after buying an additional 300 shares during the period. FMR LLC grew its position in shares of Enovis by 20.5% during the 3rd quarter. FMR LLC now owns 2,840 shares of the company’s stock worth $122,000 after buying an additional 484 shares in the last quarter. XTX Topco Ltd purchased a new position in shares of Enovis during the third quarter valued at $217,000. Finally, Legacy Capital Wealth Partners LLC bought a new stake in shares of Enovis in the fourth quarter valued at about $228,000. 98.45% of the stock is owned by hedge funds and other institutional investors.

Enovis Stock Performance

Shares of Enovis stock opened at $35.55 on Tuesday. Enovis Co. has a one year low of $35.14 and a one year high of $62.79. The company has a market capitalization of $2.02 billion, a PE ratio of -16.23 and a beta of 2.05. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27. The company has a 50-day simple moving average of $43.90 and a two-hundred day simple moving average of $43.98.

Enovis (NYSE:ENOV) last posted its earnings results on Wednesday, February 26th. The company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.92 by $0.06. The company had revenue of $560.98 million during the quarter, compared to analysts’ expectations of $555.14 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. Research analysts expect that Enovis Co. will post 2.79 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Needham & Company LLC dropped their target price on shares of Enovis from $65.00 to $64.00 and set a “buy” rating on the stock in a report on Thursday, February 27th.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.